Detalhe da pesquisa
1.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
2.
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
Res Sq
; 2023 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36798177
3.
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
JCO Precis Oncol
; 4: 882-897, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050761
4.
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Trials
; 20(1): 264, 2019 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31138317
5.
Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Lancet Respir Med
; 4(12): 980-989, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27773665